BackgroundBreast cancer is one of the most common malignant tumors in women worldwide. Histamine (HIS) has been associated with either pro-tumor or anti-tumor effects, depending on the receptor evaluated.
It exerts its physiological and pharmacological functions through four receptors (H1R-H4R). In breast cancer, it promotes tumor growth by activating H1 and H2 receptors.
Furthermore, HIS released into the tumor microenvironment can promote inflammation associated with tumor development and immunosuppression of the immune response. Several years ago, breast cancer was shown to express the H4R, although conflicting data exist; its activation is associated with tumor progression and the development of metastases.Methods and ResultsIn this study, using a murine model of breast cancer with the 4T1 cell line, we investigated in depth the role of H4R in tumor progression.
We demonstrated that H4R blockade with the specific antagonist JNJ777120 (JNJ) inhibits tumor cell line proliferation, migratory capacity, and ROS production, while increasing lactate release and rapidly and transiently ERK kinase activation.
Frontiers in Immunology published a clinical update in Infectious Disease on 21 Apr 2026.
The item focuses on Targeting histamine H4 receptor improves anti-tumoral response in a murine model of breast cancer.
Review the original article for the full source wording and details.